Treatment using Oxaliplatin and S-1 Adjuvant chemotherapy for Stage III gastric cancer trial - TOSA trial

Department of Surgery, Kochi Medical School0 个研究点目标入组 75 人开始时间: 2017年1月30日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Synchronous or metachronous malignant disease, or multicentric cancer. 2. Serious postoperative morbidity such as serious infection, anastomotic leakage, gastrointestinal bleeding and so on. 3. Serious concurrent disease such as intestinal palsy, small bowel obstraction, interstitial pneumonia, pulmonary fibrosis, uncontrolable diabetes mellitus, heart failure, renal failure, liver cirrhosis, hepatic failure, and so on. 4. Active infectious disease. 5. Positive of HBs antigen or HCV antibody. 6. Continuous treatment with steroids. 7. Serious diarrhea. 8. A medical history of serious allergy to any drug. 9. Ascites beyond the pelvic cavity or pleural effusion. 10. Brain metastasis. 11. Taking flucytosine or phenytoin. 12. Needs of taking warfarin potassium. 13. Sensory neuropathy caused by any drug. 14. A history of blood transfusion or administration of granulocyte-colony stimulating factor within 3 weeks before enrollment. 15. Women who are pregnant or hope to become pregnant during the study period. 16. Patients judged inappropriate for the study by their physicians.

发起方

Department of Surgery, Kochi Medical School